[{"address1": "1359 Broadway", "address2": "Suite 1710", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "212 433 3791", "website": "https://zentalis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 124, "companyOfficers": [{"maxAge": 1, "name": "Ms. Andrea  Paul J.D.", "age": 42, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 682466, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Julie M. Eastland M.B.A.", "age": 59, "title": "CEO, President & Director", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vincent  Vultaggio", "age": 40, "title": "VP of Finance & Interim Principal Accounting Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Lackner Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Chief Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ingmar  Bruns M.D., Ph.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.13, "open": 3.08, "dayLow": 3.01, "dayHigh": 3.19, "regularMarketPreviousClose": 3.13, "regularMarketOpen": 3.08, "regularMarketDayLow": 3.01, "regularMarketDayHigh": 3.19, "beta": 1.742, "forwardPE": -1.0388579, "volume": 901726, "regularMarketVolume": 901726, "averageVolume": 2113364, "averageVolume10days": 948340, "averageDailyVolume10Day": 948340, "bid": 3.09, "ask": 3.15, "bidSize": 300, "askSize": 300, "marketCap": 220210080, "fiftyTwoWeekLow": 2.66, "fiftyTwoWeekHigh": 18.07, "priceToSalesTrailing12Months": 5.4292426, "fiftyDayAverage": 3.3188, "twoHundredDayAverage": 7.005375, "currency": "USD", "enterpriseValue": -127775912, "floatShares": 51058808, "sharesOutstanding": 71265400, "sharesShort": 4669830, "sharesShortPriorMonth": 7052724, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0655, "heldPercentInsiders": 0.09445, "heldPercentInstitutions": 0.98014, "shortRatio": 3.17, "shortPercentOfFloat": 0.1319, "impliedSharesOutstanding": 79689696, "bookValue": 4.98, "priceToBook": 0.6204819, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -179284000, "trailingEps": -2.5, "forwardEps": -3.57, "enterpriseToRevenue": -3.15, "enterpriseToEbitda": 0.614, "52WeekChange": -0.7773775, "SandP52WeekChange": 0.2764505, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ZNTL", "underlyingSymbol": "ZNTL", "shortName": "Zentalis Pharmaceuticals, Inc.", "longName": "Zentalis Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1585920600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "39a4bee6-8ddb-3930-b936-d5bcf9eb8cf7", "messageBoardId": "finmb_647536411", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.09, "targetHighPrice": 20.0, "targetLowPrice": 4.0, "targetMeanPrice": 9.5, "targetMedianPrice": 8.0, "recommendationKey": "none", "numberOfAnalystOpinions": 10, "totalCash": 391252000, "totalCashPerShare": 5.49, "ebitda": -207958000, "totalDebt": 43266000, "quickRatio": 7.13, "currentRatio": 7.294, "totalRevenue": 40560000, "debtToEquity": 12.211, "revenuePerShare": 0.572, "returnOnAssets": -0.2524, "returnOnEquity": -0.42891, "freeCashflow": -81906872, "operatingCashflow": -171756992, "grossMargins": 1.0, "operatingMargins": -5.1594396, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]